Steven J Lahti1, Minzhi Xing1, Di Zhang2, James J Lee3, Michael J Magnetta1, Hyun S Kim4. 1. Division of Interventional Radiology, Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 2. Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania. 3. Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania. 4. Division of Interventional Radiology, Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.. Electronic address: kevin.kim@yale.edu.
Abstract
PURPOSE: To evaluate Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation status as a prognostic factor for survival after yttrium-90 ((90)Y) radioembolization for colorectal cancer (CRC) liver metastases. MATERIALS AND METHODS: Consecutive patients with unresectable CRC liver metastases and documented KRAS mutation status who were treated with (90)Y radioembolization during the period 2007-2014 were investigated. Patient demographics, disease characteristics, therapy regimens, and overall survival (OS) from first (90)Y radioembolization were compared between patients with KRAS wild-type (wt) and mutant status. Kaplan-Meier estimation and Cox regression were used for survival analysis and to assess independent prognostic factors for OS. RESULTS: Of 186 patients, 104 underwent KRAS mutation analysis before (90)Y radioembolization, with 45 (43.3%) identified as mutant. The wt and mutant groups were similar in demographics, liver status, overall performance status, and tumor characteristics (all P > .05). Mean time from liver metastasis to (90)Y radioembolization was greater in patients with KRAS wt status (P = .033). A greater percentage of wt patients received anti-epidermal growth factor receptor therapies before (90)Y radioembolization (66.1% vs 8.9%; P < .001). Median OS from first (90)Y radioembolization was significantly greater in KRAS wt patients (9.5 mo vs 4.8 mo; P = .041). Univariate analysis identified Child-Pugh class, carcinoembryonic antigen (CEA), chemotherapy after (90)Y radioembolization, KRAS status, and treatment-induced toxicity as prognostic factors for OS. Multivariate Cox regression analysis demonstrated Child-Pugh class, CEA, and KRAS status to be independent prognostic factors for OS, even when correcting for the effect of chemotherapy after (90)Y radioembolization. CONCLUSIONS: Patients with CRC and KRAS wt may derive greater survival benefit from (90)Y radioembolization therapy than patients with KRAS mutant.
PURPOSE: To evaluate Kirsten ratsarcoma viral oncogene homolog (KRAS) mutation status as a prognostic factor for survival after yttrium-90 ((90)Y) radioembolization for colorectal cancer (CRC) liver metastases. MATERIALS AND METHODS: Consecutive patients with unresectable CRC liver metastases and documented KRAS mutation status who were treated with (90)Y radioembolization during the period 2007-2014 were investigated. Patient demographics, disease characteristics, therapy regimens, and overall survival (OS) from first (90)Y radioembolization were compared between patients with KRAS wild-type (wt) and mutant status. Kaplan-Meier estimation and Cox regression were used for survival analysis and to assess independent prognostic factors for OS. RESULTS: Of 186 patients, 104 underwent KRAS mutation analysis before (90)Y radioembolization, with 45 (43.3%) identified as mutant. The wt and mutant groups were similar in demographics, liver status, overall performance status, and tumor characteristics (all P > .05). Mean time from liver metastasis to (90)Y radioembolization was greater in patients with KRAS wt status (P = .033). A greater percentage of wt patients received anti-epidermal growth factor receptor therapies before (90)Y radioembolization (66.1% vs 8.9%; P < .001). Median OS from first (90)Y radioembolization was significantly greater in KRAS wt patients (9.5 mo vs 4.8 mo; P = .041). Univariate analysis identified Child-Pugh class, carcinoembryonic antigen (CEA), chemotherapy after (90)Y radioembolization, KRAS status, and treatment-induced toxicity as prognostic factors for OS. Multivariate Cox regression analysis demonstrated Child-Pugh class, CEA, and KRAS status to be independent prognostic factors for OS, even when correcting for the effect of chemotherapy after (90)Y radioembolization. CONCLUSIONS:Patients with CRC and KRAS wt may derive greater survival benefit from (90)Y radioembolization therapy than patients with KRAS mutant.
Authors: May Cho; Jonathan Kessler; John J Park; Aram Lee; Jun Gong; Gagandeep Singh; Yi-Jen Chen; Philip H G Ituarte; Marwan Fakih Journal: J Gastrointest Oncol Date: 2017-08
Authors: D Rohan Jeyarajah; Maria B Majella Doyle; N Joseph Espat; Paul D Hansen; David A Iannitti; Joseph Kim; Thavam Thambi-Pillai; Brendan C Visser Journal: J Gastrointest Oncol Date: 2020-04
Authors: Etay Ziv; Michael Bergen; Hooman Yarmohammadi; F Ed Boas; E Nadia Petre; Constantinos T Sofocleous; Rona Yaeger; David B Solit; Stephen B Solomon; Joseph P Erinjeri Journal: Oncotarget Date: 2017-04-04
Authors: E Janowski; O Timofeeva; S Chasovskikh; M Goldberg; A Kim; F Banovac; D Pang; A Dritschilo; K Unger Journal: Oncol Rep Date: 2016-11-29 Impact factor: 3.906
Authors: Thomas Walter; Neil S Hawkins; Richard F Pollock; Fabien Colaone; Suki Shergill; Paul J Ross Journal: J Cancer Res Clin Oncol Date: 2020-07-27 Impact factor: 4.553